Cerus Corporation 2016 Q3 Form 10-Q Summary
Business context and reporting period
Cerus develops and commercializes the INTERCEPT Blood System for pathogen reduction of platelets and plasma; its red blood cell system remains in development. This unaudited Form 10-Q covers the three and nine months ended September 30, 2016, compared with the corresponding 2015 periods. Cerus operated in one blood-safety segment and had 103.5 million common shares outstanding as of October 27, 2016.
Financial performance and position
| Metric | Q3 2016 | Q3 2015 | 9M 2016 | 9M 2015 |
|---|---|---|---|---|
| Total revenue | $10.4 million | $8.0 million | $27.3 million | $24.6 million |
| Product revenue | $10.2 million | $8.0 million | $27.1 million | $24.6 million |
| Government contracts revenue | $0.3 million | — | $0.3 million | — |
| Gross profit on product revenue | $4.7 million | $2.5 million | $12.4 million | $7.3 million |
| Realized product gross margin | 46% | 31% | 46% | 30% |
| Loss from operations | $(14.3) million | $(16.2) million | $(46.3) million | $(46.1) million |
| Net loss | $(14.4) million | $(15.7) million | $(49.4) million | $(41.1) million |
| Net loss per diluted share | $(0.14) | $(0.17) | $(0.49) | $(0.48) |
- Product revenue increased 26% in Q3 and 10% for the first nine months, primarily from higher disposable-kit volume in European and Middle Eastern markets.
- Gross margin benefited principally from elimination of Fenwal royalties after June 30, 2015, lower obsolescence and manufacturing charges, and higher sales volume.
- Research and development expense was $7.0 million in Q3, down 9%, but $22.5 million for nine months, up 22%, reflecting red blood cell clinical development and platelet/plasma regulatory work.
- Selling, general and administrative expense increased 11% in Q3 and 5% year to date, driven by U.S. commercialization and BARDA-related activities.
- Interest expense rose to $1.9 million for nine months from $1.1 million. The prior-year periods included $1.1 million and $4.7 million of warrant-revaluation gains; no such gains occurred in 2016.
- Cash used in operating activities was $43.8 million for nine months versus $42.3 million in 2015. Investing cash use was $38.6 million, while financing provided $24.3 million, including approximately $22.0 million of net proceeds from an at-the-market equity offering.
- At September 30, 2016, cash and cash equivalents were $12.9 million, short-term investments were $63.4 million, and the Aduro marketable equity investment was $4.9 million. Total debt was approximately $19.4 million, consisting of $5.0 million current and $14.4 million non-current debt.
- Total assets were $116.1 million and stockholders’ equity was $72.3 million, compared with $139.4 million and $94.8 million, respectively, at December 31, 2015. Working capital declined to $85.1 million from $108.5 million.
Material changes, outlook, and unusual items
- Cerus entered into a five-year BARDA agreement in June 2016. The base period provides funding of up to $30.8 million, with potential total funding of up to $180.5 million if option periods are exercised. Cerus recognized $0.3 million of BARDA revenue in the first nine months. BARDA may terminate the agreement for convenience, and funding is subject to milestones, audits, appropriations, and option exercises.
- The company expects continued losses and additional spending for U.S. commercialization, post-approval studies, red blood cell development, regulatory activities, and BARDA obligations. Management stated that available cash, investments, product receipts, and expected BARDA receipts should fund requirements for at least the next twelve months, but this conclusion depends on assumptions that may prove incorrect.
- The red blood cell system remains subject to clinical, regulatory, manufacturing, and funding risks. A CE mark submission was anticipated for the fourth quarter of 2016; U.S. commercialization would require additional studies and a license-enabling Phase III trial.
- The Oxford Finance loan was amended in July 2016 to extend the interest-only period through January 2017. Principal and interest payments then resume, with the loans maturing June 1, 2019. The company did not meet the revenue threshold required to draw the remaining $10.0 million tranche.
- Manufacturing and development obligations to Fresenius totaled $5.0 million on the balance sheet, with an additional contractual payment of approximately $6.2 million expected when specified production volumes are achieved or by December 31, 2022, whichever is earlier.
- Cerus relies substantially on Fresenius and other sole or limited-source suppliers. Supply interruptions, component shortages, manufacturing nonconformities, product recalls, or required regulatory approval of redesigned illuminators could affect revenue and margins.
- No legal proceedings were reported. Management concluded disclosure controls were effective as of September 30, 2016, and reported no material changes in internal control over financial reporting.
Most important facts for investors to verify
- Whether U.S. adoption of the platelet and plasma systems accelerates sufficiently to offset continuing operating cash burn.
- The pace and profitability of product revenue growth, including customer concentration, European and CIS exposure, currency effects, and reimbursement developments.
- Actual BARDA funding received, option-period exercises, milestone performance, audit outcomes, and any potential co-investment obligations.
- Progress, cost, safety results, and regulatory timing for the red blood cell system and required platelet post-approval studies.
- Liquidity relative to ongoing operating losses, approximately $19.4 million of debt, $6.2 million of Fresenius obligations, and $38.99 million of disclosed contractual commitments.
- Availability and cost of future equity or debt financing, including dilution risk under the remaining $62.3 million capacity of the Cantor at-the-market agreement.
- Exposure to sole-source manufacturing, regulatory compliance, intellectual-property claims, foreign exchange volatility, and marketable equity value changes related to Aduro.